Cheng Yung-Yi, Tsai Tung-Hu
Institute of Traditional Medicine, National Yang-Ming University , Taipei 112, Taiwan.
Graduate Institute of Acupuncture Science, China Medical University , Taichung 404, Taiwan.
J Agric Food Chem. 2017 Feb 8;65(5):1078-1085. doi: 10.1021/acs.jafc.6b04975. Epub 2017 Jan 30.
The International Agency for Research on Cancer (IARC) demonstrated rhodamine B as a potential carcinogen in 1978. Nevertheless, rhodamine B has been illegally used as a colorant in food in many countries. Few pharmacokinetic and toxicological investigations have been performed since the first pharmacokinetic study on rhodamine B in 1961. The aims of this study were to develop a simple and sensitive high-performance liquid chromatography method with fluorescence detection for the quantitative detection of rhodamine B in the plasma and organs of rats and to estimate its pharmacokinetics and biodistribution. The results demonstrated that the oral bioavailabilities of rhodamine B were 28.3 and 9.8% for the low-dose and high-dose exposures, respectively. Furthermore, rhodamine B was highly accumulated in the liver and, to a lesser extent, the kidney, but was undetectable in the brain. These results provide useful information for improving the pharmacokinetics and biodistribution of rhodamine B, supporting additional food safety evaluations.
国际癌症研究机构（IARC）在1978年证实罗丹明B是一种潜在致癌物。然而，在许多国家，罗丹明B仍被非法用作食品中的着色剂。自1961年首次对罗丹明B进行药代动力学研究以来，很少进行药代动力学和毒理学研究。本研究的目的是建立一种简单、灵敏的高效液相色谱荧光检测法，用于定量检测大鼠血浆和器官中的罗丹明B，并评估其药代动力学和生物分布。结果表明，低剂量和高剂量暴露下罗丹明B的口服生物利用度分别为28.3%和9.8%。此外，罗丹明B在肝脏中高度蓄积，在肾脏中的蓄积程度较小，但在大脑中未检测到。这些结果为改善罗丹明B的药代动力学和生物分布提供了有用信息，有助于进一步的食品安全评估。
